SHH and pilomatrixoma: Therapeutic indication: Various types of cancerTarget: Transcriptional regulatory proteinCategory 1• 6-month study shows pilomatricoma• Complex pharmacology underlying Shh and catenin signaling, proposed mode of action resulting in pilomatricoma• No genotoxicity, no immunosuppressive effects